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Detection of Xenoestrogens in Serum after Immunoprecipitation of
Endogenous Steroidal Estrogens
Kala Natarajan,1 James W. Overstreet,1 Jane M. Rogers,2 Michael S. Denison,2 Jiangang Chen,1
Peter N. Lohstroh,1 Daniel S. McConnell,3 and Bill L. Lasley1
1Center for Health and the Environment and 2Department of Environmental Toxicology, University of California, Davis, California, USA;
3University of Michigan, Ann Arbor, Michigan, USA
A great deal of public concern is currently
focused on environmental hazards that may
have the potential to disrupt endocrine func-
tion. Many of these endocrine disruptors
have been linked to adverse effects on either
embryonic development or reproductive
function in wildlife and humans (1–3).
Exposures to these chemicals have been
shown to stimulate sex hormone signal
transduction pathways in vitro (4–6) and to
cause developmental defects in fish (7) and
reptiles (8,9) and egg-shell thinning in birds
(10). Nevertheless, the adverse effects of
endocrine disruptors on human reproductive
health have not been convincingly demon-
strated (11). Recently, it has been suggested
that in utero exposure to environmental
estrogens or other endocrine disruptors may
be responsible for a global decline in sperm
counts of adult men (12–15). Such expo-
sures also have been suggested to cause early
puberty in girls (16). Although numerous
environmental agents have been shown to
have estrogenic activity and thus the poten-
tial to exert adverse effects either by acting
through the estrogen receptor (ER) and/or
by activating estrogen-induced genes (17),
documentation of adverse outcomes in
humans as a result of exposures to environ-
mental estrogens is lacking.
Previous attempts to link adverse health
outcomes with exposures to environmental
endocrine disruptors have been hampered by
technical limitations in the methodology for
exposure assessment. In many cases, the
putative endocrine disruptor may be
unknown and/or sensitive assays may not
be available to allow accurate measurement
of the chemical agent in biologic samples.
Even when the chemical agent is known,
analytic measurements of the compound in
body fluids provide no information as to
its ability to produce a biologic effect at the
detected concentration. Functional assays,
which can measure the biologic activity of
a compound or mixture of compounds,
have the potential to provide valid and rel-
evant exposure assessments. However,
when such assays are applied to biologic
samples, they must be able to distinguish
the natural, endogenous hormone receptor
ligands from the xenoligand mimic(s). In
this article, we report the results of experi-
ments that address this problem by a
process of immunoprecipitation and
removal of all biologically active, endoge-
nous estrogens from serum, followed by
measurements of estrogen action with a
functional cell-based bioassay for ER-
dependent transcriptional activation lig-
ands. Measurements of total ER-mediated
cell signals before and after the removal of
endogenous steroidal estrogens enable
detection of environmental estrogens
within a biologic sample as well as assess-
ment of their relative biologic activity in
the presence of the endogenous steroidal
estrogens.
Materials and Methods
Reagents. We obtained radiolabeled estradiol
(14C-E2) and estrone (14C-E1) from NEN
Life Science Inc. (Boston, MA); 17β-estra-
diol (17β-E2) from Steraloids Inc. (Wilton,
NH); nonylphenol (NP) from Aldrich
Chemical Co. (Milwaukee, WI); α-mini-
mum essential medium (αMEM), geneticin,
fetal bovine serum (FBS), and sodium bicar-
bonate solution from Gibco BRL (Grand
Island, NY); phenol red-free Dulbecco’s
modified Eagle medium, trypsin, goat anti-
rabbit IgG, normal rabbit serum, and human
serum from Sigma Chemical Company (St.
Louis, MO); charcoal/dextran-treated FBS
from Hyclone (Logan, UT); lysis buffer from
Promega (Madison, WI); and luciferin from
BD PharMingen (San Diego, CA).
We raised polyclonal antibodies in two
male rabbits (R614 and R624) to an
immunogen that consisted of estradiol-6-
carboxy-oxime (Sigma Chemical Company)
conjugated to bovine serum albumin
(CalBiochem, La Jolla, CA) using a mixed
anhydride reaction. Both antisera exhibited
100% cross-reactivity to E2 and partial cross-
reactivity to E1 when titrated against 14C-E.
The cross-reactivity for E1 was 81% for
R614 and 16% for R624. We pooled retired
clinical serum samples from females to
obtain human serum pools.
Immunoprecipitation. Radiolabeled
estrogens from human serum. We spiked
each of three 100-µL aliquots of human
serum (Sigma) with 2 nCi 14C-E2 and 2 nCi
14C-E1. We treated one of the three aliquots
with 100 µL of a 1:5 dilution of R614 and
100 µL of a 1:10 dilution of R624. Two
control aliquots received the same volume of
phosphate buffer (pH 7). After samples were
incubated at 4°C for 18 hr, we added 50 µL
of the precipitating antibody (goat anti-rab-
bit IgG) and 5 µL normal rabbit serum to
the sample that received the antiestrogen
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In this article we report a simple and efficient method for detecting nonsteroidal estrogens in a
biologic sample. This method uses polyclonal antibodies to estradiol (E2) to immunoprecipitate
these major biologically active steroidal estrogens, leaving behind the nonsteroidal estrogens,
which are then detected in a cell-based transcriptional activation bioassay for estrogen receptor
agonist. The immunoprecipitation method effeciently removed 99% of radiolabeled E2 and
estrone (E1) from human serum. In experiments in which supraphysiologic concentrations of E2
and E1 to human serum, all of the immunoreactive estrogens were still removed by the immuno-
precipitation protocol. We carried out an in vivo validation study of this method in which we
treated female macaques with the xenoestrogen nonylphenol (NP), during the late follicular phase
of the menstrual cycle. We used blood samples collected before and after treatment to evaluate
and characterize endogenous and exogenous serum estrogens. An immunoassay for E2 did not
detect the NP in treated monkeys. The cell-based bioassay also did not detect the estrogenic activ-
ity of NP because of its saturation by the endogenous serum steroidal estrogens. However, when
steroidal estrogens were removed by immunoprecipitation, we detected the estrogenic activity of
NP in the bioassay. Thus, this approach is appropriate for detecting exogenous, nonsteroidal
estrogens in serum samples. Key words: cell bioassay, endocrine disruptors, nonylphenol, steroidal
estrogens, xenoestrogens. Environ Health Perspect 110:791–795 (2002). [Online 17 June 2002]
http://ehpnet1.niehs.nih.gov/docs/2002/110p791-795natarajan/abstract.html
antibodies and to one of the control samples
(secondary antibody control). The second
control sample (total count control) received
an equal volume of buffer. After a second
18-hr incubation period at 4°C, we cen-
trifuged all samples at 18,000 × g for 30 min
at 4°C. We recovered the supernatants and
centrifuged them a second time following
the same protocol. Finally, 100-µL aliquots
of the supernatants were combined with 10
mL of scintillation fluid and counted for 1
min in a scintillation counter. We repeated
the experiment three times.
Estrogens from untreated serum and
serum spiked with supraphysiologic levels
of E2 and E1. We prepared four 100-µL
aliquots of pooled human serum. We spiked
two of the four samples with 2,000 pg/mL
E2 and 2,000 pg/mL E1. The remaining two
samples received no additional estrogen. We
processed one of the estrogen-spiked serum
samples and one of the untreated serum
samples by immunoprecipitation with R614
and R624 as described above. The two con-
trol samples (one estrogen spiked and one
untreated) received phosphate buffer rather
than antiestrogen antisera. We incubated
and centrifuged the samples as described
above in preparation for analysis by
immunoassay or bioassay (see below). We
repeated the experiment three times with
different pools of human serum.
Estrogens from serum spiked with NP
or with NP, E2, and E1. We spiked each of
four 100-µL aliquots of pooled human
serum with 250 pg/mL NP. Two of the four
samples also received 2,000 pg/mL E2 and
2,000 pg/mL E1. We processed one of the
samples treated with NP alone and one of
the samples treated with NP and estrogens
by immunoprecipitation with R614 and
R624 as described above. The two control
samples (one treated with NP and one
treated with NP and estrogens) received
phosphate buffer rather than antiestrogen
antisera. We incubated and centrifuged the
samples as described above in preparation for
analysis by immunoassay or bioassay (see
below). We repeated the experiment three
times with different pools of human serum.
Treatment of macaques with NP. Three
mature female cynomolgus macaques
(Macaca fascicularis) were individually
housed at the California Regional Primate
Research Center in compliance with the fed-
eral Animal Welfare Act and the National
Institutes of Health Guide for the Care and
Use of Laboratory Animals (18). All animals
experienced regular menstrual cycles as
determined by daily observations of the per-
ineum. We administered NP (15 mg/kg
body weight/day in corn oil) for 3 successive
days by nasogastric intubation during the
late follicular phase of the menstrual cycle,
beginning on cycle day 9. We collected
blood samples from the saphenous vein from
physically restrained, unanesthetized ani-
mals. We collected 5 mL of blood 1 day
before the first treatment and every day after
treatment for 5 consecutive days.
Estrogen immunoassay. We detected
estrogens in human serum and monkey
serum by immunoassay using the ACS-180
automated chemiluminescence analyzer
(Bayer Diagnostics Corporation,Tarrytown,
NY). We modified the ACS:180 (E2-6)
immunoassay to enhance sensitivity by alter-
ing and lengthening the incubation condi-
tions. The modified immunoassay involves
incubation of the sample with a rabbit anti-
E2–6 antibody and subsequent addition of a
dimethylacridinium ester-labeled derivative
of E2. Final incubation of sample with label
and separation of antibody bound and free
all take place after the samples have been
placed on the ACS:180. The working assay
range is 1.0–250 pg/mL.
ER bioassay. Dose–response curve for
the induction of luciferase activity by E1, E2,
and NP. The bioassay for detecting estrogen-
dependent activation of gene expression was
originally developed by Rogers and Denison
(6). This assay consists of human ovarian car-
cinoma cells (BG1) that have been stably
transfected with a luciferase reporter gene
plasmid under the regulation of four estro-
gen-response elements. These cells are able to
detect estrogenic chemicals by ER-mediated
transactivation of the reporter gene. We per-
formed the bioassay as previously described
(6) with slight modification. Briefly, we grew
transfected BG1Luc4E2 cells in normal cell
culture medium (MEM with 10% FBS).
When the cells reached approximately
90–95% confluency, they were washed with
phosphate-buffered saline, trypsinized for 30
sec, dispersed with cell culture medium, and
plated in 150-mm dishes. The next day, after
plating, we removed the media and overlaid
the cells with estrogen-depleted phenol red-
free media (Sigma) supplemented with 10%
charcoal-dextran-treated FBS (Hyclone). The
cells were maintained in the estrogen-
depleted media for 6 days, dispersed with
estrogen-depleted media, and then plated in
96-well microtiter plates. After 24-hr incuba-
tion, we removed media; overlaid the cells
with 250 µL of estrogen-depleted media con-
taining increasing concentrations of each of
E1, E2, and NP at 1% final volume; and
incubated them for an additional 24 hr. The
media were then removed and the cells were
lysed using 100 µL of 1X lysis buffer
(Promega). We measured luciferase activity
in 45 µL of lysate in a Dynatech ML2550
microtiter-plate luminometer (Dynatech
Laboratories Inc., Chantilly, VA), after the
addition of 100 µL luciferase reagent with a
delay time of 2 sec and integration time of 2
sec. Luciferase activity was expressed as rela-
tive light units per milligram of protein. The
minimal detection limits were 1 pM for E2,
10 pM for E1, and 1 nM for NP. 
Detection of estrogenic chemicals. We
maintained cells as described above; after 24
hr incubation in 96-well microtiter plates,
we removed media and overlaid the cells
with 250 µL of estrogen-depleted media
containing E2 standards and test serum at
1% final volume. We then incubated the
cells for an additional 24 hr and determined
the luciferase activity as described above.
Calculation of data. We calculated data
using an enzyme immunoassay (EIA) pro-
gram designed by Dennis R. Stewart
(Enzyme Immunoassay Program, version
5.2; University of California, Davis, CA). 
Calculation of standard curve. The EIA
program calculates standard curves using the
2+2 logistic log algorithm (19). Basically,
this is a four-parameter logistic log regres-
sion, except the parameters are fitted two at
a time. The data are fitted according to the
equation
[1]
where Y = the luciferase activity (optical den-
sity); X = the concentration of the standard
(E2); A = The zero dose response; B =
–(slope of the logit–log plot); C = dose for
50% binding; and D = infinite dose response
(maximal luciferase activity measured for a
ligand).
The four parameters fitted are A, B, C,
and D. These were fitted two at a time. First,
we performed a weighted logit–log regression
to obtain B and C, which the program used to
then calculate A and D, ending the first itera-
tion. The program does five iterations and
then determines standard residual variance.
The program also calculates the root mean
square error, which is a measure of goodness
of fit of the line through the points and the
standard errors of the fitted parameters.
Y
A – D
X
C
D ,
B
=
+  
+
1
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Table 1. Immunoprecipitation of radiolabeled
estrogens from human serum.
Sample cpm Percent
Total counta 4,177 ± 24.0 100 ± 0
Secondary antibodyb 3,916 ± 5.5 93.7 ± 0.24
Immunoprecipitatedc 51 ± 9.0 1.2 ± 0.022
cpm, counts per minute. Values shown are mean ± SD; n
= 3. Values of secondary antibody control and that of
immunoprecipitated samples are percentage of total
count control. All samples were spiked with 2 nCi 14C-E2
and 2 nCi 14C-E1. 
aTreated with buffer only. bTreated with goat anti-rabbit
IgG only. cTreated with rabbit antisera raised against E1
and E2 followed by goat anti-rabbit.
Calculation of unknowns. Unknowns
were calculated as E2 equivalents. The pro-
gram calculates the zero dose and the infinite
dose for each plate and the percentage bind-
ing based on this and relates them back to
the standard curve. The information on the
number of replicates (which is 3 for this
study) is in the format files. The program
processes the information and calculates the
amount of ligand present (unknowns) based
on the standard curve.
We analyzed all samples in triplicate and
considered each plate to be an individual
assay with standard curve and internal con-
trols included. The interassay coefficients of
variation for low and high internal controls
(n = 10) were 4.5% and 5.2%, respectively.
The intraassay coefficients of variation for
low and high internal controls (n = 20) were
11.5% and 14.3%, respectively. The sensi-
tivity of the assay for E2, defined as 2 SDs
above the average zero dose, was 20 pg/mL.
Statistical methods. We calculated
descriptive statistics and comparative analysis
(Student’s test between controls and experi-
mentals) using Microsoft Excel (Microsoft,
Redmond, WA).
Results
Immunoprecipitation of estrogens from
human serum. Human serum spiked with a
mixture of radiolabeled E2 and E1 and then
treated with polyclonal antibodies raised
against the two hormones removed 99% of
the added hormones by immunoprecipitation
(Table 1). We considered the level of radioac-
tivity after addition of the labeled hormones
to be 100%, and after immunoprecipitation,
the percentage of radioactivity remaining in
the samples was 1.22 ± 0.22 (mean ± SD, n =
3; Table 1). In control samples, treated with
the secondary antibody only, the percentage
of radioactivity after the immunoprecipitation
procedure was 93.76 ± 0.24.
Immunoassay of the untreated serum
pool revealed that the levels of immunoreac-
tive estrogens were 364.45 ± 65.25 pg/mL
(mean ± SD, n = 3; Figure 1A). After
immunoprecipitation, no estrogens were
detected by immunoassay in the serum pool
(Figure 1A). After the pooled serum was
spiked with 2,000 pg/mL of E2 and E1, we
detected the added hormones by immunoas-
say; immunoprecipitation also reduced these
supraphysiologic estrogen levels to unde-
tectable levels (Figure 1A).
When we analyzed the same serum sam-
ples using the bioassay, the levels of luciferase
induction correlated with the level of estro-
gens. The immunoprecipitation procedure
removed both the endogenous estrogens and
the added estrogens from the serum pool
(Figure 1B).
Detection of the estrogenic activity of NP
in human and macaque serum. When we
spiked samples of the pooled human serum
with NP and then treated them with the
antiestrogen antibodies, we still detected ER-
dependent induction of luciferase activity
with the bioassay (Figure 2). After we spiked
the serum with a mixture of NP, E2, and E1,
we observed a significant increase in ER-
dependent induction of luciferase activity.
Most, but not all, of this activity was
removed by immunoprecipitation with the
antiestrogen antibodies (Figure 2). The level
of signal remaining after immunoprecipita-
tion was similar to that of serum spiked with
NP alone (Figure 2).
We determined the dose dependence of
induction of luciferase activity in BG1Luc4E2
cells by incubating the cells with an increasing
concentration of E1, E2, and NP (10–14 to
10–6 M) (Figure 3). Induction of luciferase
activity was dose dependent, with a minimal
detection limit of 1 pM for E2, 10 pM for E1,
and 1 nM for NP (Figure 3). The estrogenic
potency of NP as determined by the bioassay
was 1,000 times less than that of E2 (Figure 3).
Preliminary experiments in vitro verified
that estrogenic activity of NP could be
detected in the macaque serum using the
same protocol for immunoprecipitation with
antiestrogen antibodies followed by the
bioassay for ER-dependent induction of
luciferase activity. Serum samples obtained
from macaques treated with NP revealed
physiologically normal levels of immunore-
active E2 (90–120 pg/mL) before and after
the administration of NP. After immunopre-
cipitation, however, we did not detect
immunoreactive E2 (< 2 pg/mL) (Figure
4A). Similarly, the bioassay revealed little
change in the total bioactive estrogen con-
centration before and after NP administra-
tion. However, after immunoprecipitation,
approximately 5–10% of the previous total
estrogen bioactivity remained and increased
during the 3 days that animals received NP
(Figure 4B).
Discussion
Estrogenic endocrine disruptors include
natural substances in food (isoflavinoids and
lignans), nonsteroidal pharmaceuticals
(diethlystilbestrol and ethinyl estradiol), and
synthetic chemical compounds that degrade
slowly and bioaccumulate in the environ-
ment (polychlorinated biphenyls and
alkylphenols). After gaining entry into the
body, compounds that are ER-ligand mimics
are able to bind to the ER on target cells and
then act as agonists or antagonists, altering
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Figure 1. Effect of immunoprecipitation with antiestrogen antibodies on levels of (A) immunoreactive estrogen and (B) bioactive estrogen in human serum. Bars
show estrogen levels for untreated, pooled human serum samples (control), pooled serum samples immunoprecipitated with antiestrogen antibodies (E-precipi-
tated), pooled serum samples spiked with E2 and E1 (E-spiked), and E-spiked samples after immunoprecipitation (E-spiked E-precipitated). Values shown are ± SD
of triplicate determinations. 
*Values significantly different from the unprecipitated samples at p < 0.05, as determined by t-test. 
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the ability of endogenous steroids to exert an
action by virtue of competitive binding to
the ER. The same compound may act as a
weak agonist alone but may exert antagonis-
tic effects in the presence of a more potent
ER ligand. Because most nonsteroidal estro-
gens are not tightly bound by circulating
binding proteins in human blood, they have
an advantage over endogenous estrogens in
terms of competing for ER binding because
they are unimpeded by carrier proteins.
However, because nonsteroidal estrogens can
exert a wide range of biologic effects that are
determined partly by other compounds in
circulation, direct measurements of their
concentrations may not be biologically rele-
vant even when the identity of the estrogenic
compound is known. Functional assays can
estimate the biologic activity of a wide range
of compounds, whether or not the chemical
structures are known, but these assays can-
not distinguish between exogenous and
endogenous estrogenic compounds, and they
cannot determine the effects of individual
chemicals when a mixture of compounds is
present. The present study is a first step in
addressing these issues and describes a
method that separates steroidal estrogens
from xenoestrogens in blood samples and
then estimates the biologic activity of the
xenoestrogens.
We selected NP as a model environmen-
tal estrogen because of its well-defined estro-
genic properties (4,20) and widespread use.
In agricultural and industrial communities,
alkylphenols are commonly used as wetting
agents for pesticides that are delivered to a
wide range of crops and, as such, have wide-
spread destination. The potential adverse
effects of NP have been investigated in vitro,
and NP has been shown to stimulate growth
in E2-dependent MCF-7 cells (20), stimu-
late vitellogen production in cultured trout
hepatocytes (4), and bind and activate lig-
and-dependent gene transcription in ER-
transfected mammalian and yeast cells
(4–6). In vivo studies have demonstrated the
ability of NP to increase uterine growth in
rodents after treatment with NP (6). The
toxicology of NP has not been investigated
previously in primate models.
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Figure 3. Dose–response curve for the induction of luciferase activity by E1, E2,
and NP after incubation of the cells with the indicated concentration of E1, E2,
and NP. RLU, relative light units. Values shown are mean. of triplicate determi-
nations. The minimal detection limit were 1 pM for E2, 10 pM for E1, and 1 nM
for NP. The arrow indicates the sensitivity of the immunoassay for E2. 
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Figure 4. Detection of the estrogenic activity of NP in macaque serum after oral administration of NP for 3 consecutive days. (A) Immunoreactive estrogen levels.
(B) Levels of estrogen bioactivity. Bars show estrogen levels on the day before NP administration (0 hr), and on 4 successive days after NP administration (24–96
hr). E-unprecipitated indicates estrogen levels in untreated serum samples, and E-precipitated indicates estrogen levels in the same serum samples after
immunoprecipitation with antiestrogen antibodies. Values shown are mean ± SD of three determinations.
*Values significantly different from the unprecipitated samples at p < 0.05, as determined by t-test. 
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Figure 2. Detection of the estrogenic activity of NP in human serum. Bars show
bioactive estrogen levels for pooled human serum samples spiked with NP (NP-
spiked); NP-spiked samples after immunoprecipitation with antiestrogen anti-
bodies (NP-spiked E-precipitated); pooled serum samples spiked with NP, E2,
and E1 (NPE-spiked); and NPE-spiked samples after immunoprecipitation (NPE-
spiked E-precipitated). Values shown are mean ± SD of triplicate determinations. 
*Values significantly different from the unprecipitated samples at p < 0.05, as determined
by t-test.
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We used a sensitive immunoassay and a
cell-based bioassay in this study to demon-
strate that immunoprecipitation effectively
separates endogenous steroidal estrogens from
exogenous xenoestrogens in human serum
samples. Both of these assays confirmed that
immunoprecipitation of human serum sam-
ples with antiestrogen antibodies completely
removed 14C-labeled E1 and E2 from the
sample. Other experiments demonstrated
that the immunoprecipitation method was
able to reduce normal concentrations of
endogenous ER-binding ligands and supra-
physiologic concentrations of E1 and E2 to
nondetectable levels. Nevertheless, in future
studies with other species or types of biologic
samples, antibodies to additional steroidal
estrogens may be required to remove endoge-
nous estrogens that compete for ER binding.
When we added the xenoestrogen NP to
serum samples either alone or in combina-
tion with supraphysiologic concentrations of
E2, NP was not removed by immunoprecipi-
tation, and we subsequently detected it with
the bioassay for ER-dependent induction of
luciferase activity. The measurement of ER-
dependent induction of luciferase activity
before and after the removal of steroidal
estrogens provides an avenue to measure the
relative inducing activity of any xenoestro-
gens that are present in the sample as well as
information on their biologic activity in vivo.
In our in vivo experiments with macaques,
we detected the estrogenic activity of NP
exposure only after immunoprecipitation of
steroidal estrogens.
In summary, we have developed a
method for detection of xenoestrogens in
biologic samples. This approach can be use-
ful in epidemiologic studies for exposure
assessment and risk assessment. The method
can be used for exposure assessment to deter-
mine which members of a population have
been exposed to potential endocrine disrup-
tors. Traditional analytic chemistry methods
would then be needed to identify specific
compounds or classes of estrogenic com-
pounds to which the subjects were exposed.
In other situations in which xenoestrogens
have been identified in the circulation of
exposed individuals, our approach of com-
paring the total ER-dependent inducing
activity in the presence and absence of
endogenous estrogens can provide important
information for assessment of the level of
risk to the exposed population. This assay
can, for the first time, clearly demonstrate
the existence of the biologic activity of non-
steroidal estrogens in serum without interfer-
ence from steroidal estrogens.
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